We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 36 for:    PREMIUM

PREMIUM, Observational Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01756625
Recruitment Status : Unknown
Verified December 2012 by Dr.Laurent Mineur, Institut Sainte Catherine.
Recruitment status was:  Active, not recruiting
First Posted : December 27, 2012
Last Update Posted : December 27, 2012
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
PREMIUM is an observational pharmaco-epidemiologic, transversal, multi-centric, prospective cohort study and with independent investigators. The purpose is to compare PFS in real life with PFS clinical trials and to determine factors impacting efficacy and compliance to cetuximab treatment in first line K-ras wild-type (wt) metastatic colorectal cancer.

Condition or disease
First Line WT KRAS mCRC

Detailed Description:
Retrospective studies have shown the influence of some factors on the efficacy of treatment with cetuximab (nicotine, magnesium etc..). No randomized study has compared the mode of administration of weekly and biweekly cetuximab. What are the factors influencing patient compliance? Adverse events, the relation between doctor and patient. PREMIUM will attempt to explore and assess the variables associated with efficacy and compliance to treatment and study practices in France for clinical management.

Study Design

Study Type : Observational
Actual Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer
Study Start Date : January 2010
Primary Completion Date : March 2012
Estimated Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab
U.S. FDA Resources

Groups and Cohorts

Group/Cohort
First line WT KRAS mCRC


Outcome Measures

Primary Outcome Measures :
  1. To compare PFS rate at 1 year with PFS in clinical studies (ITT and subgroup analysis) [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. ORR at 1 year (ITT and subgroup analysis) [ Time Frame: 3 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients from private and public centers
Criteria

Inclusion Criteria:

  • patients > 18 years old diagnosed with mCRC
  • patients naïve for CT excepted for adjuvant setting or trated max 2 cycles CT in first line mCRC with or without cetuximab
  • all patients receiving cetuximab in first line treatment associated or not with CT
  • patients relapsed < 6 months after an adjuvant therapy

Exclusion Criteria:

  • patients participating to clinical trials
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01756625


Locations
France
Institut Sainte-Catherine
Avignon, Vaucluse, France, 84000
Sponsors and Collaborators
Dr.Laurent Mineur
Merck Serono International SA
BESPIM, CHU Nîmes (data analysis)
More Information

Responsible Party: Dr.Laurent Mineur, Oncologist, Institut Sainte Catherine
ClinicalTrials.gov Identifier: NCT01756625     History of Changes
Other Study ID Numbers: PREMIUM
First Posted: December 27, 2012    Key Record Dates
Last Update Posted: December 27, 2012
Last Verified: December 2012

Keywords provided by Dr.Laurent Mineur, Institut Sainte Catherine:
cetuximab
nicotine
magnesium

Additional relevant MeSH terms:
Cetuximab
Antineoplastic Agents